GILEAD SCIENCES SL
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection
- Conditions
- Interventions
- First Posted Date
- 2012-07-27
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 90
- Registration Number
- NCT01651403
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇮🇳SMS Medical College and Hospital, Jaipur, Rajasthan, India
🇷🇴Grigore Alexandrescu Emergency Clinical Hospital for Children, Bucharest, Romania
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
- Conditions
- Interventions
- First Posted Date
- 2012-07-17
- Last Posted Date
- 2016-05-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 107
- Registration Number
- NCT01641822
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Indiana University, Indianapolis, Indiana, United States
🇺🇸Riley Hospital for Children, Indianapolis, Indiana, United States
Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection
- First Posted Date
- 2012-07-17
- Last Posted Date
- 2014-05-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 328
- Registration Number
- NCT01641640
- Locations
- 🇺🇸
Peter J. Ruane, MD, Inc., Los Angeles, California, United States
🇺🇸Borland-Groover Clinic Baptist, Jacksonville, Florida, United States
🇺🇸Infectious Disease Specialist of Atlanta, Decatur, Georgia, United States
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-06-29
- Last Posted Date
- 2021-08-12
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 515
- Registration Number
- NCT01631552
- Locations
- 🇺🇸
Massachusettes General Hospital, Boston, Massachusetts, United States
🇺🇸Texas Oncology Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Helen F. Graham Cancer Center, Newark, Delaware, United States
Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies
- First Posted Date
- 2012-06-21
- Last Posted Date
- 2015-11-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 534
- Registration Number
- NCT01625338
- Locations
- 🇺🇸
Lightsource Medical/Peter J. Ruane MD, Inc., Los Angeles, California, United States
🇺🇸California Liver Institute, Los Angeles, California, United States
🇺🇸Anthony Mills MD, Inc., Los Angeles, California, United States
Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-05-24
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 92
- Registration Number
- NCT01605318
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Helen F. Graham Cancer Center-Christiana Care, Newark, Delaware, United States
🇺🇸The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)
- Conditions
- Interventions
- First Posted Date
- 2012-05-24
- Last Posted Date
- 2014-05-28
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 202
- Registration Number
- NCT01604850
- Locations
- 🇨🇦
Toronto Liver Centre, Toronto, Ontario, Canada
🇺🇸Gastrointestinal Specialists of Georgia, PC, Marietta, Georgia, United States
🇺🇸Texas Clinical Research Institute, LLC, Arlington, Texas, United States
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2012-05-04
- Last Posted Date
- 2013-08-13
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 51
- Registration Number
- NCT01591668
- Locations
- 🇺🇸
Avail Clinical Research, LLC, DeLand, Florida, United States
🇵🇷Fundacion De Investigacion De Diego, Santurce, Puerto Rico
🇺🇸CliniLabs, New York, New York, United States
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2012-05-03
- Last Posted Date
- 2013-11-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 49
- Registration Number
- NCT01590641
- Locations
- 🇦🇺
Royal Perth Hospital, Nedlands, Western Australia, Australia
🇨🇦Algorithme Pharma, Inc., Montreal, Quebec, Canada
🇨🇦University of Alberta Hospital, Edmonton, Alberta, Canada
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
- Conditions
- Interventions
- First Posted Date
- 2012-05-03
- Last Posted Date
- 2013-12-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 51
- Registration Number
- NCT01590654
- Locations
- 🇺🇸
Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States